Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response after COVID-19 vaccination in patients with renal failure stage 4 or 5
2021-000988-68Phase 4Completed
- Sponsor
- Region Stockholm
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ChAdOx1 nCoV-19, tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) and kidney failure, sponsored by Region Stockholm. Primary endpoint: SARS-CoV-2 IgG seroconversion or ≥10^2 increase in neutralizing antibodies after vaccination. Started Mar 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)kidney failure
Beyond the preview
Go deeper on 2021-000988-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000988-68.